<DOC>
	<DOC>NCT01560546</DOC>
	<brief_summary>A randomized, placebo-controlled, double-blinded study on 40 men with type 2 DM. Type 2 diabetes mellitus (T2DM) is a common endocrine disorder characterized by hyperinsulinaemia and insulin resistance. Hypothesis Testosterone therapy increases lean body mass and insulin sensitivity in men with low normal levels of bioavailable testosterone and type 2 DM.</brief_summary>
	<brief_title>Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM)</brief_title>
	<detailed_description>Background Inadequate levels of androgens have been associated with an increased risk of chronic illnesses including obesity and diabetes. Moreover, testosterone treatment has been shown to increase lean body mass and lipid oxidation as well as insulin sensitivity in hypogonadal men.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male gender age 5070 Bioavailable testosterone &lt; 7,3 nmol/L Metformin treatment of T2DM for 3 months or more HbA1c &gt; 9,0 %, BMI &gt; 40 kg/m2, Haematocrit &gt; 50%, Known malignant disease, PSA &gt; 3 ug/L, Nycturia &gt; 3 times, Abnormal routine blood samples, Severe hypertension, Significant EKGchanges, Wish of parenthood, Active mental illness, former or present abuse, Severe illness of heart, lung or kidney, Primary or secondary hypogonadism.</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>